BioAtla and GATC Health announce $40 million SPV transaction to advance ozuriftamab vedotin into a registrational trial for 2L+ OPSCC: San Diego Saturday, January 3, 2026, 18:00 H ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback